Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging

European Urology

Volumn 59, Issue 1, 2011, Pages 96-105

  Auprich, Marco ^a   Chun, Felix K H ^b   Ward, John F ^c   Pummer, Karl ^a   Babaian, Richard ^c   Augustin, Herbert ^a   Luger, Ferdinand ^a   Gutschi, Stefan ^a   Budäus, Lars ^b   Fisch, Margit ^b   Huland, Hartwig ^b   Graefen, Markus ^b   Haese, Alexander ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Locally advanced prostate cancer; Low volume prostate cancer; Pathologically confirmed insignificant prostate cancer; Urinary prostate cancer antigen 3

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; AUSTRIA; BIOPSY; CHI-SQUARE DISTRIBUTION; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TEXAS; TUMOR BURDEN;

EID: 78650250585     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.10.024     Document Type: Article

References (33)

1. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151
2. M.R. Cooperberg, J.M. Broering, P.W. Kantoff, and P.R. Carroll Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 2007 S14 S19
3. J.W. Saranchuk, M.W. Kattan, E. Elkin, A.K. Touijer, P.T. Scardino, and J.A. Eastham Achieving optimal outcomes after radical prostatectomy J Clin Oncol 23 2005 4146 4151 (Pubitemid 46211320)
4. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
5. N. Suardi, U. Capitanio, and F.K. Chun Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features Cancer 113 2008 2068 2072
6. S.E. Eggener, K.A. Roehl, and W.J. Catalona Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy J Urol 174 2005 500 504
7. J.I. Epstein, P.C. Walsh, M. Carmichael, and C.B. Brendler Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
8. P.J. Bastian, L.A. Mangold, J.I. Epstein, and A.W. Partin Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis Cancer 101 2004 2001 2005
9. C. Jeldres, N. Suardi, and J. Walz Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men Eur Urol 54 2008 1306 1313
10. F.K. Chun, A. Haese, and S.A. Ahyai Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men Cancer 113 2008 701 709
11. M. Ohori, M.W. Kattan, and H. Koh Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer J Urol 171 2004 1844 1849 discussion 1849
12. T. Steuber, M. Graefen, and A. Haese Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy J Urol 175 2006 939 944 discussion 944
13. F.K.-H. Chun, T. Steuber, and A. Erbersdobler Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology Eur Urol 49 2006 820 826
14. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809 discussion 1809-10
15. M.P. van Gils, D. Hessels, and C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215 1222
16. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978 discussion 1978-9
17. D. Hessels, M.P. van Gils, and O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10 16
18. S. Loeb Does PCA3 help identify clinically significant prostate cancer? Eur Urol 54 2008 980 981
19. J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095
20. J.E. McNeal, E.A. Redwine, F.S. Freiha, and T.A. Stamey Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread Am J Surg Pathol 12 1988 897 906
21. M. Amin, L. Boccon-Gibod, and L. Egevad Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens Scand J Urol Nephrol Suppl 2005 20 33
22. M.E. Chen, D. Johnston, A.O. Reyes, C.P. Soto, R.J. Babaian, and P. Troncoso A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume Am J Surg Pathol 27 2003 1291 1301
23. F.K. Chun, A. de la Taille, and H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 668
24. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535
25. M.A. Uhlman, L. Sun, and D.A. Stackhouse Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology 75 2010 460 466
26. A. Briganti, F.K. Chun, and N. Suardi Prostate volume and adverse prostate cancer features: fact not artifact Eur J Cancer 43 2007 2669 2677
27. R. Simon, and D.G. Altman Statistical aspects of prognostic factor studies in oncology Br J Cancer 69 1994 979 985
28. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
29. H. Bialkowska-Hobrzanska, D.K. Driman, R. Fletcher, V. Harry, and H. Razvi Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue Can J Urol 13 2006 2967 2974
30. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
31. U. Schmidt, S. Fuessel, and R. Koch Quantitative multi-gene expression profiling of primary prostate cancer Prostate 66 2006 1521 1534
32. M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
33. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538